Showing 4611-4620 of 9153 results for "".
- Venus Concept Announces Medical Advisory Board for AI.ME, Its Next Generation Robotic Platformhttps://practicaldermatology.com/news/venus-concept-announces-medical-advisory-board-for-aime-its-next-generation-robotic-platform/2461872/Meet Venus Concept Inc.’s medical advisory board for AI.ME, its next generation robotic platform. The primary mission of the medical advisory board will be to provide strategic input, guidance, and clinical recommendations regarding the Company's emerging robotic technolo
- FDA Clears Xstrahl’s Radiant Aura for NMSCshttps://practicaldermatology.com/news/fda-clears-radiant-aura-receives-us-food-and-drug-administration-fda-510k-clearance/2461871/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Xstrahl’s Radiant Aura, an office-based radiation therapy for non-melanoma skin cancer (NMSC). “We developed Radiant Aura to deliver both electronic brachytherapy and superficial radiation therapy in
- Warts and All: Novan Files Chapter 11, Sells Assetshttps://practicaldermatology.com/news/warts-and-all-novan-files-chapter-11-sells-assets/2461870/Novan is selling all of its assets, including Berdazimer Gel, 10.3% (SB206), and has filed for Chapter 11 Protection. The Company entered into a stalking horse asset purchase agreement (APA) with Ligand Pharmaceuticals, Inc. prior to filing voluntary petitions for relief unde
- Arcutis’ ZORYVE Now in Preferred Position on National Formularies for CVS Caremarkhttps://practicaldermatology.com/news/arcutis-zoryve-now-in-preferred-position-on-national-formularies-for-cvs-caremark/2461868/Arcutis Biotherapeutics, Inc.’s ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on national formularies for CVS Caremar
- EULAR Seeks to Classify Risk of PsA in PsO Patientshttps://practicaldermatology.com/news/eular-seeks-to-classify-risk-of-psa-in-pso-patients/2461867/New EULAR points-to-consider characterize the transition from skin to joint involvement in psoriatic disease. Overall, five overarching principles and 10 points-to-consider were formulated by a multidisciplinary task force of 30 members from 13 European countries. The principles ac
- Acclaro Medical Rebrands UltraClear Cold Fiber Laserhttps://practicaldermatology.com/news/acclaro-medical-rebrands-ultraclear-cold-fiber-laser/2461866/Meet the newly re-branded UltraClear Cold Fiber Laser from Acclaro Medical. From a design perspective, rebranding encompasses an updated logo and color palette and aims to increase recognition of UltraClear's 3DIntelliPulse technology and its ability to provide optima
- News You Can Use: GW, Pfizer Offering Grants to Improve Access to Teledermatology in Underserved Areashttps://practicaldermatology.com/news/news-you-can-use-gw-pfizer-offering-grants-to-improve-access-to-teledermatology-in-underserved-areas/2461865/The George Washington University (GW) School of Medicine and Health Sciences (SMHS) and Pfizer Global Medical Grants are collaborating to offer a grant opportunity focused on broad implementation of GW’s Teledermatology Help Desk Clinic model in underserved areas across the United States.</
- Revian Red Hair Growth System Takes on CCCA in Second Studyhttps://practicaldermatology.com/news/revian-red-hair-growth-system-takes-on-ccca-in-second-study/2461864/Revian Red Hair Growth System is planning a second study to build on previous trial results as an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). The Revian Red Hair Growth System is a US Foof and Drug Administration- cleared, lightweight wirel
- Study: DermaSensor Correctly Identifies 96.2% of Melanomas in Senior Citizenshttps://practicaldermatology.com/news/study-dermasensor-correctly-identifies-962-of-melanomas-in-senior-citizens/2461863/DermaSensor correctly identified 96.2% of melanomas in patients 65 and older, according to a sub-analysis of the DERM-ASSESS III study data of Medicare-eligible patients that was presented at the Annual American Dermoscopy Meeting. The sensitivity of the DermaSensor device for melanoma
- DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its Melanoma Testhttps://practicaldermatology.com/news/dermtech-adds-approximately-7-million-covered-lives-for-the-foundational-assay-of-its-melanoma-test/2461861/DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced a favorable coverage policy from Highmark Inc. (Highmark). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, We